A Study of BG-C477 in Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06596473

Public ClinicalTrials.gov record NCT06596473. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.

Study identification

NCT ID: NCT06596473
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: BeOne Medicines; Industry
Enrollment: 310 participants

Conditions and interventions

Conditions

Advanced Solid Tumors

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 3, 2024 (Actual)
Primary completion: Dec 31, 2027 (Estimated)
Completion: Dec 31, 2027 (Estimated)
Last update posted: Sep 14, 2026

2024 – 2027

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
City of Hope Phoenix Cancer Center	Goodyear	Arizona	85338	Recruiting
City of Hope National Medical Center	Duarte	California	91010-3012	Recruiting
University of Colorado Cancer Center	Aurora	Colorado	80045-2517	Recruiting
Yale University Yale Cancer Center	New Haven	Connecticut	06520-8028	Recruiting
Osf Saint Francis Medical Center	Peoria	Illinois	61637	Recruiting
The University of Kansas Cancer Center	Westwood	Kansas	66205-2003	Recruiting
University of Mississippi Medical Center (Ummc)	Jackson	Mississippi	39216	Recruiting
John Theurer Cancer Center Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
The University of Texas Md Anderson Cancer Center	Houston	Texas	77030-4009	Recruiting
Texas Oncology Longview	Longview	Texas	75601	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06596473, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 14, 2026 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06596473 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →